SCHEMBL14472602

SCHEMBL14472602

Cc1ccc(/C=C/C(=O)O)cc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.70
HSD17B10 Q99714 3/20 0.70
CA12 O43570 3/20 0.70
CA1 P00915 3/20 0.70
CA2 P00918 3/20 0.70
CA3 P07451 3/20 0.70
CA4 P22748 3/20 0.70
CA6 P23280 3/20 0.70
CA5A P35218 3/20 0.70
CA7 P43166 3/20 0.70
CA9 Q16790 3/20 0.70
CA14 Q9ULX7 3/20 0.70
CA5B Q9Y2D0 3/20 0.70
AKR1B10 O60218 3/20 0.70
AKR1B1 P15121 3/20 0.70
DPP4 P27487 3/20 0.70
ALDH1A1 P00352 3/20 0.70
MAPK1 P28482 3/20 0.70
TTR P02766 3/20 0.70
HPGD P15428 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21986902 0.85 IAPP (0.73) KDM4EHSD17B10CA12CA1CA2
SCHEMBL21986720 0.85 IAPP (0.73) KDM4EHSD17B10CA12CA1CA2
SCHEMBL471934 0.85 KDM4E (0.70) KDM4EHSD17B10CA12CA1CA2
SCHEMBL471935 0.85 KDM4E (0.70) KDM4EHSD17B10CA12CA1CA2
SCHEMBL584596 0.85 KDM4E (0.58) KDM4EHSD17B10CA12CA1CA2
SCHEMBL111230 0.85 KDM4E (0.58) KDM4EHSD17B10CA12CA1CA2
SCHEMBL21986709 0.84 PELI1 (0.53) KDM4EHSD17B10CA12CA1CA2
SCHEMBL27524820 0.84 KDM4E (0.68) KDM4EHSD17B10CA12CA1CA2
SCHEMBL30739974 0.84 PELI1 (0.53) KDM4EHSD17B10CA12CA1CA2
SCHEMBL27524817 0.84 KDM4E (0.68) KDM4EHSD17B10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11717549-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2023-08-08 US disclosed
US-11701400-B2 Steviol glycoside compositions with reduced surface tension CARGILL, INCORPORATED (US) 2023-07-18 US disclosed
US-20170080040-A1 DECOCTION OF OLIVE LEAVES EVERGREEN LIFE PRODUCTS S.R.L. (IT) 2017-03-23 US disclosed
US-9512063-B2 Process for the preparation of advantame DIVI'S LABORATORIES LIMITED (IN) 2016-12-06 US disclosed
US-20160304439-A1 PROCESS FOR THE PREPARATION OF ADVANTAME DIVI'S LABORATORIES LIMITED (IN) 2016-10-20 US disclosed
US-9394555-B2 Compositions comprising a polypeptide having cellulolytic enhancing activity and a dioxy compound and uses thereof NOVOZYMES, INC. (US) 2016-07-19 US disclosed
US-20130157317-A1 Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Dioxy Compound And Uses Thereof NOVOZYMES, INC. (US) 2013-06-20 US disclosed
US-20070174933-A1 Altering levels of anti-nutrient factors in plants HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD (CA) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701400-B2 Steviol glycoside compositions with reduced surface tension STT3A, SIGLEC7, STT3B KDM4E 4391/4885HSD17B10 473/4885CA12 289/4885
US-11717549-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 KDM4E 3664/4885HSD17B10 827/4885CA12 1617/4885
US-20160304439-A1 PROCESS FOR THE PREPARATION OF ADVANTAME TASP1, ASPH, COMT KDM4E 563/4885HSD17B10 1152/4885CA12 4666/4885
US-20170080040-A1 DECOCTION OF OLIVE LEAVES ELOVL5, ALOX5, LIPA KDM4E 1793/4885HSD17B10 191/4885CA12 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.